Reach Us +1 850 754 6199

ISSN: 2576-1439

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Variation in Utilization and Spending for the Management of Actinic Keratosis

Variation in Utilization and Spending for the Management of Actinic Keratosis

Importance: In 2004, the US health care spending for actinic keratosis (AK) management was $1.2 billion so any change in the money spent per person could equate to large cost differences due to the high prevalence.
Objective: To assess AK-specific healthcare utilization and costs and the impact of minimizing extremes of utilization and spending.
Methods: Retrospective cohort study, using data from a large private insurer for the mid-Atlantic region for the period of January 2010 to December 2012.
Results: The total cost of AK-related care was $40,719,495 for 95,294 patients with AK; prescriptions accounted for 8.6% and outpatient care for 91.4%. The use of extensive destruction (CPT 17004), prescription therapy, male gender and age were associated with a higher mean three-year cost per patient. The mean threeyear cost was $447.74; when outliers outside of the 1st and 99th percentile and 5th and 95th percentiles were replaced, the mean decreased by about $35 or $64, respectively.
Conclusions and relevance: Age, gender, and treatment factors all influence the total cost of AK management. The mean and total costs for are sensitive to the effects of outliers.

Special Features

Full Text

View

Track Your Manuscript

Share This Page

Media Partners

Associations